HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Ocular Therapeutix (NASDAQ:OCUL) and maintained a price target of $14.
June 14, 2024 | 10:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Ocular Therapeutix and maintained a price target of $14, indicating continued confidence in the company's stock performance.
The reiteration of a Buy rating and the maintenance of a $14 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and support the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100